Skip to main content
. Author manuscript; available in PMC: 2023 Nov 24.
Published in final edited form as: J Hepatol. 2021 Apr 12;75(2):424–434. doi: 10.1016/j.jhep.2021.03.013

Fig. 3. The late time-point miRNA-based model.

Fig. 3.

(A) miRNA included within the model. (B) Model performance (n = 175; AUC 0.83 [95% CI 0.76–0.89; p <0.0001*]; pseudo r2 = 0.2767, HL statistic 11.54 [p = 0.17]). (C) MetaCore™ pathway analysis including miRNA within the model. (D) Comparisons with other outcome prediction models with and without threshold values using the DeLong method. Statistical significance set as per Benjamini-Hochberg procedure with a false discovery rate of 0.05 (*p <0.026). ALFSGPI, Acute Liver Failure Study Group prognostic index; HL, Hosmer-Lemeshow; KCC, King’s College criteria; MELD, model for end-stage liver disease; miR/miRNA, microRNA; OR, odds ratio.